Pharmacogenomics · 2012 · 26 citations · 37 references
PharmacyPharmacokineticsPharmacologyPharmacogeneticsPharmacogenomicsPharmacogenomics In OncologyCancer PharmacogenomicsDrug Transporter GeneticsToxicity GradingToxicity Risk AssessmentAbcb1 Genetic VariationDrug Toxicity RiskDrug Trough ConcentrationErlotinib TherapyNon-small Cell Lung Cancer TherapyNon-small Cell Lung Cancer TreatmentPharmacogenetic Variant FrequenciesTaqman Genotyping Assays
AIMS: We analyzed the association of ABCB1 polymorphisms with erlotinib-induced toxicity and the pharmacokinetics in patients with non-small-cell lung cancer. MATERIALS & METHODS: After erlotinib 150 mg was administered to 50 patients, ABCB1 polymorphisms were analyzed via either TaqMan(®) assays or direct nucleotide sequencing. Plasma concentrations were measured by HPLC. RESULTS: The trough concentration at steady state in patients with the ABCB1 1236TT-2677TT-3435TT genotype was higher compared with others groups (p = 0.021) and patients carrying this genotype had a higher risk of developing higher grade 2 toxicity (p = 0.012). CONCLUSION: The present study suggested that the ABCB1 1236TT-2677TT-3435TT genotype was associated with higher plasma concentration and the risk of developing higher toxicity in patients treated with erlotinib.
37
<i>EGFR</i> Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
J. Guillermo Paez, Pasi A. Jänne, Jeffrey C. Lee et al. · Science · 2004 · 9.4K citations
A "Silent" Polymorphism in the <i>MDR</i> 1 Gene Changes Substrate Specificity
Chava Kimchi‐Sarfaty, Jung Mi Oh, In‐Wha Kim et al. · Science · 2006 · 2.5K citations · Full text
Sven Hoffmeyer, Oliver Burk, Oliver von Richter et al. · Proceedings of the National Academy of Sciences · 2000 · 2.4K citations